ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Clinical trial NCT07452224 · RECRUITING

Trial details

NCT number: NCT07452224
Sponsor: iLeukon Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Start date: 2026-06-29
Primary completion: 2029-06-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.